Thermo Fisher Scientific announced that it will shut down its Franklin, Massachusetts manufacturing site, a decision that will eliminate roughly 80 direct jobs while relocating about 120 employees to other U.S. facilities. The closure is scheduled to be completed by the end of 2026, with layoffs taking effect between December 31 2026 and December 31 2027.
The Franklin plant has long produced air‑quality monitors, industrial hygiene instruments and flow‑computer systems—products that support environmental and process monitoring across a range of industries. Those production lines will be transferred to other Thermo Fisher sites in the United States, allowing the company to consolidate its manufacturing footprint without losing critical capabilities.
Management explained that the shutdown is part of an ongoing review of global operations aimed at improving efficiency and aligning capacity with current customer demand. CEO Marc N. Casper emphasized that the move “does not reflect a strategic change in our commitment to U.S. manufacturing” and that the company remains focused on delivering high‑margin life‑science solutions.
Thermo Fisher’s Q4 2025 results provide context for the decision. Revenue rose 7% year‑over‑year to $12.21 billion, and adjusted earnings per share climbed 8% to $6.57, beating the consensus estimate of $6.45 by $0.12. The beat was driven by strong demand in the Life Science Solutions and Biology Products & Biopharma Services segments, coupled with disciplined cost control that preserved an adjusted operating margin of 23.6%—slightly down from 23.9% in Q4 2024 but still robust. For the full year, the company guided 2026 revenue to $46.3 billion–$47.2 billion and adjusted EPS to $24.22–$24.80, a 6%–8% growth outlook that reflects confidence in continued demand and margin expansion.
Analysts have responded positively to the earnings beat, reaffirming strong‑buy ratings and maintaining target prices around $668 per share. While the 2026 guidance is considered modest, it signals management’s belief that the company can sustain profitability through cost discipline and strategic investments, such as the planned $9 billion acquisition of Clario.
The Franklin closure is part of a broader pattern of workforce adjustments. In the past year, Thermo Fisher cut about 300 jobs at viral‑vector sites in Massachusetts, announced the shutdown of another viral‑vector facility affecting 160 positions, and slated the Asheville, North Carolina plant for closure, impacting 421 employees. At the same time, the company has invested $2 billion in U.S. operations, acquired a Sanofi sterile fill‑finish facility, and opened a new manufacturing site in North Carolina. Executive departures—including COO Michel Lagarde and EVP Frederick Lowery—occurred around the same time, underscoring a period of significant organizational change.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.